Physician profile
Mohammad A Khan
NPI 1033183231
$1,885.76
in general payments reported to CMS, 2019-2025
13 companies · $429 in 2025
The $429 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $271 · 2021: $421 · 2022: $139 · 2023: $79.46 · 2024: $370 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $727 · Education: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $727.14 |
| Education | $151.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.00 | 2019-2024 | Ofev, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $328.67 | 2019-2025 | Fasenra, Breztri |
| Genzyme Corporation | $314.55 | 2019-2025 | |
| Glaxosmithkline, LLC. | $273.20 | 2020-2025 | Nucala |
| Insmed, INC. | $166.19 | 2021-2024 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $137.99 | 2019-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $124.99 | 2025 | Winrevair |
| Mallinckrodt Hospital Products INC. | $99.99 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $30.62 | 2019 | |
| Pfizer INC. | $18.87 | 2020 | |
| Vifor Pharma, INC. | $18.61 | 2024 | Zemaira |
| Allergan, INC. | $12.97 | 2019 | |
| Mylan Specialty L.P. | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.